Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in development phase under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs), to discover and treat cardiac diseases, and hematological diseases, spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Headquarters Australia

Address L 38 55 Collins St, Melbourne, Victoria, 3000


Telephone 61 3 96396036

No of Employees 83

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange MSB (ASX)

Revenue (2021) $7.5M -76.8% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -26.8% (2021 vs 2020)

Market Cap* $299.2M

Net Profit Margin (2021) XXX -446.8% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

60+

Clinical Trials

Determine Mesoblast Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

18+

Pipeline Drugs

Identify which of Mesoblast Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

13+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Mesoblast Ltd’s relevant decision makers and contact details.

8

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

7

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

1

Marketed Drugs

Understand Mesoblast Ltd’s commercialized product portfolio to stay one step ahead of the market.

1

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Pipeline RYONCIL
Remestemcel-L: REVASCOR
Steroid-Refractory Acute Graft Versus Host Disease (Children)
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Plans/Strategy In December, the company announced its plans to conduct an additional US Phase 3 trial to support submissions for potential approval in both the US and EU.
2021 Contracts/Agreements In December, the company agreed with OTAT for its proposal for pain reduction at 12 months as the primary endpoint of the next trial, with functional improvement and reduction in opioid use as secondary endpoints.
2021 Others In November, the company refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Mesoblast Ltd CSL Ltd Regeneus Ltd Acrux Ltd Exopharm Ltd
Headquarters Australia Australia Australia Australia Australia
City Melbourne Melbourne Pymble Melbourne Melbourne
State/Province Victoria Victoria New South Wales Victoria Victoria
No. of Employees 83 25,000 - 43 -
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Joseph R. Swedish Chairman Executive Board 2019 -
Silviu Itescu Chief Executive Officer; Director; Managing Director Executive Board 2011 -
Dagmar Rosa-Bjorkeson Chief Operating Officer Senior Management 2021 -
Eric Rose Chief Medical Officer Senior Management 2022 -
Andrew Chaponnel Chief Financial Officer - Interim Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer